MiNK Therapeutics (INKT) Short Interest Ratio & Short Volume

Short interest is the volume of MiNK Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 51,700 shares of INKT short. 0.52% of MiNK Therapeutics' shares are currently sold short. Learn More on MiNK Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INKT shares currently have a short interest ratio of 2.0. Learn More on MiNK Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.52% of MiNK Therapeutics' floating shares are currently sold short.

MiNK Therapeutics saw a decrease in short interest in the month of October. As of October 31st, there was short interest totaling 51,700 shares, a decrease of 20.8% from the previous total of 65,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

MiNK Therapeutics currently has issued a total of 39,550,000 shares. Some of MiNK Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. MiNK Therapeutics currently has a public float of 10,020,000 shares.

0.52% of MiNK Therapeutics' shares are currently sold short. Here is how the short interest of companies compare to MiNK Therapeutics: Elevation Oncology, Inc. (12.42%), Precision BioSciences, Inc. (5.77%), Atara Biotherapeutics, Inc. (16.03%), Celularity Inc. (6.92%), Adicet Bio, Inc. (4.17%), Cabaletta Bio, Inc. (7.59%), Vaxart, Inc. (6.35%), Rani Therapeutics Holdings, Inc. (7.18%), Journey Medical Co. (0.61%), Century Therapeutics, Inc. (10.24%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling INKT is an investing strategy that aims to generate trading profit from MiNK Therapeutics as its price is falling. INKT shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for MiNK Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INKT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INKT, twice per month. The most recent reporting period available is October, 31 2024.